A Model Predictive Control Strategy Toward Optimal Structured Treatment Interruptions in Anti-HIV Therapy

In this paper, model predictive control (MPC) strategies are applied to the control of human immunodeficiency virus infection, with the final goal of implementing an optimal structured treatment interruptions protocol. The MPC algorithms proposed in this paper use a dynamic model recently developed in order to mimic both transient responses and ultimate behavior, and to describe accordingly the different effect of commonly used drugs in highly active antiretroviral therapy (HAART). Simulation studies show that the proposed methods achieve the goal of reducing the drug consumption (thus minimizing the severe side effects of HAART drugs) while respecting the desired constraints on CD4+ cells and free virions concentration. Such promising results are obtained with realistic assumptions of infrequent (possibly noisy) measurements of a subset of model state variables. Furthermore, the control objectives are achieved even in the presence of mismatch between the dynamics of true patients and that of the MPC model.

[1]  Roland Marquet,et al.  HIV-1 reverse transcriptase inhibitors , 2007, Applied Microbiology and Biotechnology.

[2]  Daniel U. Campos-Delgado,et al.  A passivity-based approach for HIV-1 treatment scheduling , 2007, 2007 American Control Conference.

[3]  B. Bequette,et al.  A tutorial on biomedical process control , 2007 .

[4]  B. Bequette.  A critical assessment of algorithms and challenges in the development of a closed-loop artificial pancreas. , 2005, Diabetes technology & therapeutics.

[5]  Ruy M Ribeiro,et al.  Estimating drug efficacy and viral dynamic parameters: HIV and HCV , 2008, Statistics in medicine.

[6]  Julio E. Normey-Rico,et al.  Robust Predictive Control Strategy Applied for Propofol Dosing Using BIS as a Controlled Variable During Anesthesia , 2008, IEEE Transactions on Biomedical Engineering.

[7]  B. Thiers,et al.  CD4+ Count–Guided Interruption of Antiretroviral Treatment , 2007 .

[8]  Martin A Nowak,et al.  Mathematical models of HIV pathogenesis and treatment. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[9]  M A Nowak,et al.  A new theory of cytotoxic T-lymphocyte memory: implications for HIV treatment. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[10]  R. Hovorka,et al.  Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. , 2004, Physiological measurement.

[11]  L. Magni,et al.  Model Predictive Control of Type 1 Diabetes: An in Silico Trial , 2007, Journal of diabetes science and technology.

[12]  B. Adams,et al.  HIV dynamics: Modeling, data analysis, and optimal treatment protocols , 2005 .

[13]  E. Rosenberg,et al.  Limited Durability of Viral Control following Treated Acute HIV Infection , 2004, PLoS medicine.

[14]  J. Rawlings,et al.  Feasibility issues in linear model predictive control , 1999 .

[15]  M A Nowak,et al.  Viral dynamics in vivo: limitations on estimates of intracellular delay and virus decay. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Gabriele Pannocchia,et al.  Model predictive control for optimal oral anticoagulant drug administration , 2006 .

[17]  M. Nowak,et al.  Specific therapy regimes could lead to long-term immunological control of HIV. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Stephen P. Boyd,et al.  Real-time Embedded Convex Optimization , 2009 .

[19]  Xiaohua Xia,et al.  IV. Structured treatment interruptions: A control mathematical approach to protocol design , 2007 .

[20]  C. Benson,et al.  Structured treatment interruptions--new findings. , 2006, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[21]  Thomas J. McAvoy,et al.  V. Modeling and control of the anticoagulant drug heparin , 2007 .

[22]  Guanrong Chen,et al.  Feedback control of a biodynamical model of HIV-1 , 2001, IEEE Transactions on Biomedical Engineering.

[23]  H Wu,et al.  Population HIV‐1 Dynamics In Vivo: Applicable Models and Inferential Tools for Virological Data from AIDS Clinical Trials , 1999, Biometrics.

[24]  S. Joe Qin,et al.  A survey of industrial model predictive control technology , 2003 .

[25]  Stephen J. Wright,et al.  Fast, large-scale model predictive control by partial enumeration , 2007, Autom..

[26]  Manfred Morari,et al.  Control of Drug Administration During Monitored Anesthesia Care , 2009, IEEE Transactions on Automation Science and Engineering.

[27]  Xiaohua Xia,et al.  Identifiability of nonlinear systems with application to HIV/AIDS models , 2003, IEEE Trans. Autom. Control..

[28]  David Q. Mayne,et al.  Constrained model predictive control: Stability and optimality , 2000, Autom..

[29]  Manfred Morari,et al.  A new paradigm for the closed-loop intraoperative administration of analgesics in humans , 2002, IEEE Transactions on Biomedical Engineering.

[30]  Ryan Zurakowski,et al.  A model predictive control based scheduling method for HIV therapy. , 2006, Journal of theoretical biology.

[31]  R.S. Parker,et al.  A model-based algorithm for blood glucose control in Type I diabetic patients , 1999, IEEE Transactions on Biomedical Engineering.

[32]  Martin A. Nowak,et al.  Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA , 1999, The Journal of experimental medicine.

[33]  D. Wodarz,et al.  Helper-dependent vs. helper-independent CTL responses in HIV infection: implications for drug therapy and resistance. , 2001, Journal of theoretical biology.

[34]  Athanasius F. M. Marée,et al.  Small variations in multiple parameters account for wide variations in HIV–1 set–points: a novel modelling approach , 2001, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[35]  M. Nowak,et al.  Population Dynamics of Immune Responses to Persistent Viruses , 1996, Science.

[36]  Ji Hyun Ko,et al.  Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability , 2006, IEEE Transactions on Biomedical Engineering.

[37]  Matteo Bianchi,et al.  Modelling and control of HIV dynamics , 2008, Comput. Methods Programs Biomed..

[38]  M. Nowak,et al.  Transient antiretroviral treatment during acute simian immunodeficiency virus infection facilitates long-term control of the virus. , 2000, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[39]  Shuzhi Sam Ge,et al.  Nonlinear control of a dynamic model of HIV-1 , 2005, IEEE Transactions on Biomedical Engineering.

[40]  H. J. Ferreau,et al.  An online active set strategy to overcome the limitations of explicit MPC , 2008 .

[41]  Matthias Cavassini,et al.  CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial , 2006, The Lancet.

[42]  Gabriele Pannocchia,et al.  Disturbance models for offset‐free model‐predictive control , 2003 .

[43]  Claudio Cobelli,et al.  Global identifiability of nonlinear models of biological systems , 2001, IEEE Transactions on Biomedical Engineering.

[44]  Victor M. Zavala,et al.  The advanced-step NMPC controller: Optimality, stability and robustness , 2009, Autom..

[45]  Dale E. Seborg,et al.  An Improved PID Switching Control Strategy for Type 1 Diabetes , 2008, IEEE Transactions on Biomedical Engineering.

[46]  Manfred Morari,et al.  Challenges and opportunities in process control: Biomedical processes , 2001 .

[47]  Xiaohua Xia,et al.  Modelling of HIV infection: Vaccine readiness, drug effectiveness and therapeutical failures , 2007 .

[48]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.